In this video interview, David Morton, PhD, director of biostatistics at Certara, discusses how growing FDA support is accelerating the adoption of Bayesian approaches, enabling more flexible, ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study We divided the borrowing ...
Bayesian prediction and modeling have emerged as transformative tools in the design and management of clinical trials. By integrating prior knowledge with accumulating trial data, Bayesian methods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results